Source comparison
Continuous use versus cycling: what the trials documented
The community 8-on/8-off pattern is one approach; the longest controlled trial describes another. In a 16-week study of nightly GHRH-(1-29) dosing in older adults, nocturnal growth-hormone output stayed elevated across the full treatment period and IGF-1 rose
This comparison does not assign a generated winner or score.
- The community 8-on/8-off pattern is one approach; the longest controlled trial describes another. In a 16-week study of nightly GHRH-(1-29) dosing in older adults, nocturnal growth-hormone output stayed elevated across the full treatment period and IGF-1 rose and remained above baseline, with no sign of the pituitary becoming desensitized to nightly stimulation over those 16 weeks (Khorram et al., 1997). That trial did not run past 16 weeks, so it documents sustained response across that window rather than open-ended continuous use.
- Community sources therefore describe two paths. Cycled use (commonly 8 weeks on, 8 weeks off) is typically framed around cost and letting IGF-1 normalize between blocks. Continuous nightly use is supported, over the studied window, by the trial record showing maintained GH output without desensitization. Sermorelin's short half-life means each nightly dose is a single transient pulse that clears before the next, which is the mechanism most often cited for why the natural pulsatile pattern is preserved on daily dosing.